ClinicalTrials.gg
RecruitingNCT07593313Updated Nov 16, 2026

Treatment of Post-Stroke Central Pain

An interventional study of stSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) and Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) in Central Post-Stroke Pain, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2026).
  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.

Planned enrollment
135th of 212
80 · median 120
Started
2024
with 18 others
No phase
117 of 247
40 open now
Primary completion
2029-08
later than 70 of 71 live
Registered
233rd of 247
by date

Among the 247 studies in Pain with a site in China, this one is the 135th largest by planned enrollment of the 212 interventional ones that give a count, is one of 19 that started in 2024, is one of 117 with no phase, reaches primary completion later than 70 of the 71 other live ones, and was the 233rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Pain with a site in China, or all of them as a file.
02

Study summary

To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.

03

Conditions studied

  • Central Post-Stroke Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria
  • Clear history of stroke confirmed by cranial CT or MRI
  • Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury
  • Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation)
  • Pain not explained by other causes
  • Age ≥ 18 years
  • Pain duration ≥ 3 months
  • Baseline pain Numerical Rating Scale (NRS) score ≥ 4 points
  • Complete clinical data with follow-up time ≥ 6 months

Exclusion criteria

Exclusion Criteria:

  • History of chronic pain before stroke
  • Severe cognitive impairment that prevents cooperation with pain assessment (, MMSE \< 15 points)
  • to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation
  • Malignant tumors or other severe organic diseases with expected survival \< 1 year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

    Patients received conventional pharmacotherapy alone without any form of SCS.

    Drug: Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

  • Experimental
    stSCS plus Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

    Patients received stSCS in addition to conventional pharmacotherapy.

    Procedure: stSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

Interventions

  • ProcedurestSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

    Patients received stSCS in addition to conventional pharmacotherapy. stSCS Procedure: Under digital subtraction angiography (DSA) guidance, a temporary electrode (typically an 8-contact electrode) was percutaneously placed into the corresponding spinal cord segment (cervical C2-C4 or thoracic T8-T10, depending on the pain distribution area). The electrode was connected to an external stimulator to deliver continuous stimulation for 7-14 days. Stimulation parameters were as follows: frequency 40-60 Hz (conventional mode) or BurstDR mode, pulse width 210-450 μs, and amplitude individually adjusted based on the patient's sensory threshold (targeting a comfortable paresthesia covering the painful area). After the test period, the electrode was removed without a second-stage implantation. Postoperatively, patients continued receiving baseline pharmacotherapy, which could be reduced as appropriate.

  • DrugGabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

    Patients received conventional pharmacotherapy alone without any form of SCS. The medication regimen followed the 2025 International Association for the Study of Pain (IASP) recommendations, with gabapentin (starting at 300 mg/d, gradually titrated to 900-1800 mg/d based on tolerability, administered in 2-3 divided doses) or pregabalin (starting at 75 mg/d, gradually titrated to 150-300 mg/d in 2-3 divided doses) as the foundation, and could be combined with duloxetine (60-120 mg/d) or amitriptyline (25-75 mg at bedtime). Drug doses were individually adjusted by the attending physician according to patient response and tolerability.

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) score

    The primary outcome was pain intensity measured by the NRS(0-10) recorded at baseline, immediately after stimulation termination (study group)/at the corresponding time point after treatment (control group), and at 1, 3, and 6 months post-treatment. The proportions of patients with an NRS reduction of ≥30% and ≥50% from baseline were also recorded, with the latter defined as treatment response. NRS ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate worse pain.

    Time frame: Six months

Secondary outcomes

  1. Change in Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI total score ranges from 0 to 21. Higher scores indicate worse sleep quality

    Time frame: 6 months

  2. Change in Physical Health assessed by the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS)

    The SF-36 PCS score ranges from 0 to 100. Higher scores indicate better physical health

    Time frame: 6 months

  3. Change in Mental Health assessed by the 36-Item Short Form Health Survey Mental Component Summary (SF-36 MCS)

    The SF-36 MCS score ranges from 0 to 100. Higher scores indicate better mental health

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2029, 67 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 67 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Aug 2029 and completion Aug 2026 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 18, 2026
StartActual
Jan 1, 2024
Primary completionEst.
Aug 1, 2029was Aug 2026
CompletionEst.
Aug 1, 2029was Aug 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2026→Aug 1, 2029
Nov 16, 2026
Study completion
Aug 1, 2026→Aug 1, 2029
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Aug 1, 2026→Aug 1, 2029
    Study completion Aug 1, 2026→Aug 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07593313
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Jan 1, 2024
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Zhenguo Gao
Contact
gaozhenguo0822@163.com
18404999336

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion